Selecta Q3 net loss narrows to $7.9M; cash runway to mid-2024

Cartesian Therapeutics, Inc.

2022-Q3 EPS reported $0.15 revenue$93,982,000

Net loss of $7.9M ($0.05 per share) vs $17.9M loss in Q3 2021; collaboration revenue $20.7M.
Cash, equivalents & securities total $148.0M as of Sep 30, 2022; expected runway into mid-2024.
Received $10M milestone from Sobi for DISSOLVE II enrollment and $6M from Sarepta for DMD/LGMD.
Topline data from Phase 3 DISSOLVE (SEL-212 for chronic gout) expected in Q1 2023.
Phase 1 trial of SEL-302 (MMA gene therapy) on track to begin Q4 2022; IL-2 and IgA protease candidates by year-end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cartesian Therapeutics, Inc. reported financial results for quarter ended September 30, 2022.

Period: quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Selecta Biosciences, Inc. announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Cartesian Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001453687-22-000136

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.